TG 1042

Drug Profile

TG 1042

Alternative Names: Ad-IFNγ; Adenovirus interferon gamma; ASN 002 - Ascend; TG-1042

Latest Information Update: 19 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transgene
  • Developer Ascend Biopharmaceuticals; Nantes University Hospital; Transgene
  • Class Antineoplastics; Gene therapies; Immunotherapies; Interferons
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Basal cell nevus syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Basal cell cancer
  • No development reported Malignant melanoma
  • Discontinued Cutaneous B-cell lymphoma; Cutaneous T cell lymphoma

Most Recent Events

  • 03 Jun 2018 Ascend Biopharmaceuticals suspends a phase I/II trial as another protocol is being developed in Basal cell cancer in USA (Intratumoural) (NCT03208296)
  • 14 Dec 2017 Ascend Biopharmaceuticals completes a phase I/II trial in Basal cell cancer in Australia (Intratumoural) (NCT02550678)
  • 14 Dec 2017 Adverse events and efficacy data from a phase I/II trial in Basal cell cancer released by Ascend Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top